By Fineline Cube 
Shanghai ChemPartner Co., Ltd. (“ChemPartner”) and Shanghai Leado Pharma Co., Ltd. (“Leado Pharma”) have officially signed a strategic cooperation agreement, establishing a long-term and stable partnership aimed at advancing new drug research and development (R&D). This collaboration combines the expertise of both companies to enhance efficiency and resource utilization in the drug development process.
Company Profiles
ChemPartner, operating as a CRO&CDMO, is dedicated to providing comprehensive one-stop new drug R&D services for pharmaceutical companies. Leado Pharma, specializing in ion channel targets, focuses on developing new drugs for various refractory diseases. It has established a sequential R&D system prioritizing chronic pain, with multiple additional indications in development.
Collaboration Details
Through this strategic partnership, ChemPartner and Leado Pharma aim to achieve mutual benefits by sharing resources and improving R&D efficiency. Over the next five years, the collaboration will span multiple drug development areas, including chemical, biological, pharmacodynamics, pharmacokinetics, toxicology, pharmaceutical, and clinical research.
Accelerating Drug Development
The partnership will focus on advancing Leado Pharma’s new drug pipeline, accelerating the progression from the initial concept (IDEA) to the New Drug Application (NDA). This comprehensive collaboration is expected to streamline the drug development process and bring innovative treatments to market more efficiently.-Fineline Info & Tech